Autopsy report · NCT01218867

CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“No objective responses were observed.”

The sponsor’s own words in the registry.

Life of this trial

Registered 1 month before it started.
Ran for about 5 years 1 month before it stopped.
24 participants enrolled.
Results were posted on the registry 7 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 1, Phase 2
Sponsor: National Cancer Institute (NCI)
Sponsor type: US National Institutes of Health
Conditions: Metastatic Cancer; Metastatic Melanoma; Renal Cancer
Interventions: Anti-VEGFR2 CAR CD8 plus PBL; Cyclophosphamide; Aldesleukin; Fludarabine
Participants: 24
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.